Objective To compare the efficacy of zillah risperidone and risperidone in the treatment of schizophrenia. Methods In our hospital from January 2010 to January 2014,selected 60 cases schizophrenic patients hospitalized as observed object,60 cases hospitalized patients with schizophrenia during as the observed object, all patients were ran-domly divided into group A (ziprasidone) and group B (risperidone), each group of 30 patients, before and after treatment efficacy PANSS score changes and two groups of patients after treatment, adverse reactions were compared between two groups. Results After 4,8 weeks, the PANSS total score,PANSS positive symptoms, PANSS negative symptoms of A group and B group were significantly lower than before treatment,the difference was statistically signifi-cant(P<0.05),PANSS scores of A group after treatment 4,8 weeks were significantly lower than in group B,the differ-ence was statistically significant (P<0.05),but after treatment 4,8 weeks,PANSS positive symptoms, PANSS negative symptoms of group A and group B had no significant significance. The total effective rate of A group was 86.7%,was higher than that in group B (83.3%),but the difference was not statistically significant between the two groups (P>0.05). After treatment for 6 weeks,the incidence of adverse reactions of A group was 20%,group B was 40%,the inci-dence of adverse reactions in group A was significantly lower than group B,the difference was statistically significant(P<0.05). Conclusion Ziprasidone and risperidone in the treatment of schizophrenia have better efficacy, but com-pared to risperidone, ziprasidone has advantages,with fewer adverse reactions.

Objective To study the effect of venlafaxine and fluoxetine in depression and improvement on cognitive function. Methods Retrospectively analyzed from January 2012 to January 2014 in our hospital for treatment of 32 cas-es of depression with venlafaxine in patients with clinical data, set up for the observation group, selected the same pe-riod of fluoxetine in 32 patients with depression in patients with clinical data, set up as the control group, HAMD score, cognitive function before and after treatment were compared between two groups. Results The total effective rate of ob-servation group after treatment was 93.75%,was significantly higher than the control group (P<0.05). The observation group and the control group of patients with HAMD scores were significantly lower than before treatment, and the HAMD score of observation group was significantly lower than that of the control group (P<0.05). The observation group group after treatment 8 weeks, number of errors, random errors were significantly lower than before treatment, and sig-nificantly less than the control group (P<0.05). Patients in the control group after 8 weeks of treatment, number of perse-verative errors connected rates had no significant difference before treatment (P>0.05). Conclusion Venlafaxine in the treatment of depression and improve the effect on cognitive function, has more advantages than fluoxetine.

A new device that allows noninvasive measurement of venous pressure has been invented in our laboratory and tested for its feasibility and validity. The device consists of four parts: 1. the air infusion system; 2. the pressure sensor gauge; 3. signal transducer and data processing system 4. the fixing apparatus. The correlation between noninvasive pressure and invasive pressure has been studied in vitro test on a saphenous vein model and in vitro test on dog's portal venous system. In vitro and vivo study, an excellent correlation between noninvasive pressure and invasive pressure was obtained(r = 0.99, P < 0.0005; r = 0.97, P < 0.005). These data suggest that the new device allows a noninvasive measurement of venous pressure especially for the large veins such as vena cava, venae pulmonales and esophageal varices.
Animals ; Blood Pressure Determination ; instrumentation ; Dogs ; Equipment Design ; In Vitro Techniques ; Venous Pressure ; physiology